Table 6.
Antiphospholipid antibodies, thrombophilia markers and clinical characteristics of total Crohn’s disease according to presence and type of thrombosis n (%)
| Factor |
Follow-up of CD Total Cohort from diagnosis (n = 265) |
||||
| No thrombosis | Arterial thrombosis | Venous thrombosis | No pregnancy loss | Pregnancy loss | |
| (n = 251) | (n = 3) | (n = 11) | (n = 146) | (n = 10) | |
| Male/female | 104/147 | 1/2 | 7/4 | 146/0 | 10/0 |
| Age at presentation (yr)1 | 25.0 (19.0-33.0) | 40.0 (28.0-42.0) | 29.5 (23.3-39.3) | 26.0 (20.0-35.0) | 25.5 (21.0-35.0) |
| Frequent relapse | 48 (20.2) | 0 (0.0) | 4 (36.4) | 33 (24.1) | 2 (20.0) |
| Previous thrombosis | 1 (0.4)3 | 0 (0.0) | 4 (36.4)3 | 2 (1.4) | 0 (0.0) |
| Smoking habits yes | 48 (19.1) | 0 (0.0) | 3 (27.3) | 22 (15.1) | 2 (20.0) |
| Follow up time from diagnosis, mo1 | 102.2 (63.3-172.8)2 | 149.9 (130.8-219.8) | 186.3 (142.0-244.2)2 | 109.0 (61.8-184.6) | 136.5 (95.4-180.6) |
| Positive markers (%) | |||||
| Anti-β2-GPI IgG and/or IgM | 4.8 | 0 | 9.1 | 4.9 | 10 |
| Anti-β2-GPI IgA | 2.8 | 0 | 0 | 4.9 | 0 |
| ACA IgG and/or IgM | 12.1 | 0 | 27.3 | 13.9 | 10 |
| ACA IgA | 19.0 | 66.7 | 0 | 20.1 | 10 |
| Anti-PS/PT IgG and/or IgM | 14.6 | 50.0 | 36.4 | 18.3 | 40 |
| Anti-PS/PT IgA | 8.9 | 50.0 | 9.1 | 7.7 | 10 |
| At least 1 APLA pos | 48.0 | 66.7 | 54.5 | 52.8 | 60 |
| At least 2 APLA pos | 16.1 | 33.3 | 9.1 | 18.1 | 10 |
| At least 3 APLA pos | 3.2 | 0 | 9.1 | 4.9 | 0 |
| Thrombophilia markers3 (%) | |||||
| LA | 7.5 | 0 | 0 | 5.1 | 0 |
| PS deficiency (inherited and/or acquired) | 8.1 | 0 | 25.0 | 12.7 | 0 |
| ATIII deficiency (inherited and/or acquired) | 0 | 0 | 0 | 0 | 0 |
| PC deficiency (inherited and/or acquired) | 3.0 | 0 | 0 | 4.8 | 0 |
| FV Leiden | 5.94 | 0 | 42.94 | 7.8 | 0 |
| FII20210A | 5.9 | 0 | 16.7 | 7.8 | 0 |
1
Median (IQR);
2
Using Kruskal-Wallis test (P ≤ 0.01);
3
Using χ2-test with Yates correction (P ≤ 0.05);
4
Serologic and genetic markers of thrombophilia were available in 105 patients. pts: Patients; APLA: Antiphospholipid antibodies; β2-GPI: Beta2-glycoprotein-I; ACA: Anti-cardiolipin antibody; PS/PT: Phosphatidylserine/prothrombin complex.